跳至主要内容
临床试验/NCT05205954
NCT05205954招募中不适用

HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年7月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
2
主要终点
Escalation Rate

研究概览

简要总结

This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients ≥ 18 years old with diagnosis of cirrhosis based on histology, radiology, and/or elastography presenting to the emergency department or inpatient general medicine service
  • Patients must have one of the following:
  • Ascites (requiring diuretics or serial large volume paracenteses)
  • Hepatic hydrothorax (requiring diuretics)
  • Hepatic encephalopathy (requiring medications)

排除标准

  • All existing MGB home hospital criteria apply, with the following taking precedent for this specific condition
  • History of solid organ transplantation
  • On hemodialysis
  • MELD score > 20
  • Score <10 on Simplified Animal Naming Test (S-ANT1)
  • Current admission for hemodynamically significant GI bleeding or alcohol withdrawal
  • Require routine administration of controlled substances
  • Those deemed ineligible based on the MGH Home Hospital, inpatient medicine or hepatology clinician evaluation

结局指标

主要结局

Escalation Rate

时间窗: 18 months

The intervention will be deemed feasible if less than 20% of enrolled patients have escalation of care back to the inpatient (brick-and-mortar) hospital

次要结局

  • Patient Experience(Up to 90 days)
  • Adverse Event Reporting(Up to 90 days)
  • Acceptability(18 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nneka nnaoke Ufere

Assistant Professor of Medicine

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验